Vanguard Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Vanguard Capital Management's ACAD Position: Q3 2026 in Review
Vanguard Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 0.47% in Q3 2026, buying an estimated $726K and bringing the position to 5,790,801 shares worth $117M. The position accounts for ﹤0.01% of the portfolio, ranked #1435.
Vanguard Capital Management first reported a position in ACAD in Q1 2026 and has held it in 3 quarters since. The position peaked at $146M in Q2 2026. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Vanguard Capital Management held 5,790,801 shares of Acadia Pharmaceuticals worth $117M as of Q3 2026.
- Vanguard Capital Management bought 27,051 Acadia Pharmaceuticals shares in Q3 2026, an estimated $726K.
- Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1435 holding.
- Vanguard Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Acadia Pharmaceuticals position peaked at $146M in Q2 2026.
- 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.